Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07011706 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | PHASE2 | ACTIVE NOT_RECRUITING | 110 | — | — | May 30, 2025 | Oct 1, 2026 | Mar 25, 2026 | 60 | United States, Canada |
Percent change from baseline in EASI score at Week 24
| Arm | Type | Description |
|---|---|---|
| ATI-045 group | EXPERIMENTAL | ATI-045 group |
| Placebo group | PLACEBO_COMPARATOR | Placebo group |
| Name | Type | Description |
|---|---|---|
| ATI-045 | DRUG | ATI-045 group |
| Placebo | DRUG | Placebo group |
Inclusion Criteria: * Diagnosis of chronic atopic dermatitis that has been present for ≥ 6 months before the screening visit and with no significant AD flares during the past 4 weeks before screening * Have active moderate to severe AD at screening and baseline visits * EASI score ≥ 16 and ≥10% BSA...